Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $2.68, but opened at $2.95. Taysha Gene Therapies shares last traded at $3.12, with a volume of 1,228,318 shares trading hands. Analyst Ratings Changes A number of equities analysts have recently […]
Williams & Novak LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 45,000 shares of the company’s stock, valued at approximately $80,000. Several other hedge funds and other institutional […]
Canaccord Genuity Group reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report published on Thursday morning, Benzinga reports. Canaccord Genuity Group currently has a $7.00 price objective on the stock. TSHA has been the topic of a number of other research reports. Cantor Fitzgerald reissued an overweight […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation. Insider & Institutional Ownership 25.9% of […]